Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix

Objective This study elucidated the efficacy of Relugolix (REL) on the reduction of uterine volume and clinical symptoms for the treatment of adenomyosis.Methods We conducted a retrospective cohort study of patients who received REL (40 mg for about 20 weeks) and who underwent a hysterectomy for ade...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид: Keitaro Yamanaka, Keiichi Washio, Akiko Uchida, Yuki Sasagawa, Masashi Nishimoto, Yui Yamasaki, Satoshi Nagamata, Yoshito Terai
Формат: Өгүүллэг
Хэл сонгох:English
Хэвлэсэн: Taylor & Francis Group 2023-12-01
Цуврал:Gynecological Endocrinology
Нөхцлүүд:
Онлайн хандалт:https://www.tandfonline.com/doi/10.1080/09513590.2023.2237121